G 1128

Drug Profile

G 1128

Alternative Names: Anti-bcr-abl; Anticode oligonucleotides

Latest Information Update: 09 Mar 2015

Price : $50

At a glance

  • Originator Genta
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Leukaemia

Most Recent Events

  • 10 Sep 2001 Discontinued-II for Leukaemia in USA (Unknown route)
  • 03 Sep 1998 Profile reviewed
  • 20 Feb 1995 Phase-II clinical trials for Leukaemia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top